BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang T, Wu B, Hu X, Liu J, Zhang T, Li F, Sun B, Cai L, Li X, Chen Z, Yang Q, Jiang Z. A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients. Ann Transl Med 2019;7:196. [PMID: 31205914 DOI: 10.21037/atm.2019.04.10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Al-Salama ZT, Keam SJ. Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China. Clin Drug Investig 2019;39:1009-18. [PMID: 31489570 DOI: 10.1007/s40261-019-00836-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Huang X, Hu P, Zhang J. Genomic analysis of the prognostic value of colony-stimulating factors (CSFs) and colony-stimulating factor receptors (CSFRs) across 24 solid cancer types. Ann Transl Med 2020;8:994. [PMID: 32953794 DOI: 10.21037/atm-20-5363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Tirelli U, Carbone A, Di Francia R, Berretta M. A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available. Ann Transl Med 2020;8:166. [PMID: 32309313 DOI: 10.21037/atm.2019.10.61] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Wang G, Zhang Y, Wang X, Sun Q, Xun Z, Yuan M, Li Z. Long-acting versus short-acting granulocyte colony-stimulating factors among cancer patients after chemotherapy in China: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2021;100:e28218. [PMID: 34941082 DOI: 10.1097/MD.0000000000028218] [Reference Citation Analysis]
5 Ustyanovska Avtenyuk N, Visser N, Bremer E, Wiersma VR. The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. Int J Mol Sci 2020;21:E7820. [PMID: 33105656 DOI: 10.3390/ijms21217820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Xue C, Chu Q, Zheng Q, Jiang S, Bao Z, Su Y, Lu J, Li L. Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine. Signal Transduct Target Ther 2022;7:142. [PMID: 35484099 DOI: 10.1038/s41392-022-01003-0] [Reference Citation Analysis]
7 Li X, Zheng H, Yu MC, Wang W, Wu XH, Yang DM, Xu J. Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis. Support Care Cancer 2020;28:5085-97. [PMID: 32621264 DOI: 10.1007/s00520-020-05603-w] [Reference Citation Analysis]
8 Ma J, Huang H, Fu P, Xu N, Mao C, Cheng G, Yan H, Li Y, Shi Y, Wang Y, Yao Y, Chen L, Chen Y, Zhang N, Zhang G, Ren Z, Li Z, Song L, Xu R, Qin S. Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study. Ann Transl Med 2021;9:893. [PMID: 34164527 DOI: 10.21037/atm-21-2449] [Reference Citation Analysis]
9 Xu F, Zhang Y, Miao Z, Zeng X, Wu B, Cai L, Liu J, Wang S, Hu X, Zheng W, Chen Z, Yang Q, Jiang Z. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. Ann Transl Med 2019;7:482. [PMID: 31700918 DOI: 10.21037/atm.2019.07.95] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]